GTBP GT Biopharma Corporation Earnings per share growth rate in current year

Corporate emblem and logo of gtbiopharma.com (GTBP)

The monetization of immune platforms creates a foundation for future royalties from pharma behemoths for GT Biopharma, Inc. (GTBP). Annual EPS fluctuations highlight this potential, where the 0.00 level captures fresh values. Growth is driven by the digitalization of screening via AI and TriKE systems. The current development vector relies on early safety tests of new NK-cell inductors to attract strategic partners.

GTBP - GT Biopharma Earnings growth in current year over the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for GT Biopharma (GTBP)

- stock value and consensus price forecast:
Fundamental valuation:GT Biopharma Corp, GTBP
Flagship merchandise of gtbiopharma.com

This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year, reflecting the dynamics of return on equity. Growth in this metric signals effective asset monetization, which for GT Biopharma, Inc. (GTBP) depends directly on the success of the TriKE platform clinical trials in leukemia therapy. By analyzing the relative change in EPS compared to the same period last year, an investor can assess the fundamental stability of the company.